Health Catalyst, Inc. (NASDAQ:HCAT) Receives $4.32 Consensus PT from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has received a consensus recommendation of “Hold” from the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $4.3182.

Several equities research analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th. Citigroup lowered their target price on Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a research report on Friday, January 9th. Evercore ISI cut their target price on Health Catalyst from $4.00 to $3.00 and set an “in-line” rating on the stock in a research note on Wednesday, October 8th. Finally, William Blair reiterated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th.

Insider Activity

In other news, Director Julie Larson-Green sold 47,997 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the sale, the director directly owned 73,573 shares of the company’s stock, valued at approximately $196,439.91. This represents a 39.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Benjamin Landry sold 27,425 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $2.64, for a total transaction of $72,402.00. Following the completion of the transaction, the general counsel owned 100,000 shares of the company’s stock, valued at $264,000. This trade represents a 21.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HCAT. AQR Capital Management LLC boosted its stake in Health Catalyst by 816.8% during the 1st quarter. AQR Capital Management LLC now owns 168,344 shares of the company’s stock valued at $763,000 after purchasing an additional 149,981 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Health Catalyst by 7.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after buying an additional 2,624 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of Health Catalyst in the first quarter valued at $46,000. HighMark Wealth Management LLC boosted its stake in Health Catalyst by 13,080.0% during the second quarter. HighMark Wealth Management LLC now owns 164,750 shares of the company’s stock valued at $621,000 after buying an additional 163,500 shares in the last quarter. Finally, Inspire Investing LLC boosted its stake in Health Catalyst by 36.3% during the second quarter. Inspire Investing LLC now owns 103,494 shares of the company’s stock valued at $390,000 after buying an additional 27,582 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

Shares of HCAT opened at $2.21 on Friday. The company has a market cap of $156.31 million, a P/E ratio of -1.39 and a beta of 1.69. The stock has a fifty day moving average price of $2.46 and a 200 day moving average price of $2.94. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88. Health Catalyst has a 12 month low of $2.02 and a 12 month high of $5.92.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. The company had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. On average, research analysts forecast that Health Catalyst will post -0.33 earnings per share for the current year.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.